Neurim prevails against Mylan in suit over insomnia drug

Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Questions on Neurim scope remain post-SPC ruling, say lawyers

25 March 2019 The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.

Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

26 June 2020 The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Big Pharma

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

More on this story

Big Pharma

Questions on Neurim scope remain post-SPC ruling, say lawyers

Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

26 June 2020 The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Big Pharma

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

More on this story

Big Pharma

Questions on Neurim scope remain post-SPC ruling, say lawyers

Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

26 June 2020 The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Big Pharma

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.